Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five YearsGlobeNewsWire • 04/12/21
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for VitiligoGlobeNewsWire • 03/18/21
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021GlobeNewsWire • 03/17/21
Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 02/03/21
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque PsoriasisGlobeNewsWire • 02/01/21
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic DermatitisGlobeNewsWire • 01/20/21
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic DermatitisGlobeNewsWire • 01/13/21
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020GlobeNewsWire • 12/09/20
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisGlobeNewsWire • 12/07/20
Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisGlobeNewsWire • 12/01/20
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body PsoriasisGlobeNewsWire • 11/23/20
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewsWire • 11/11/20
Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic DermatitisGlobeNewsWire • 11/02/20
Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology ConferencesGlobeNewsWire • 10/30/20
Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaGlobeNewsWire • 10/26/20
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common StockGlobeNewsWire • 10/06/20